glp 1 select trial The GLP-1 Clinical Landscape in 2024 Semaglutide Effects on Cardiovascular Outcomes
Description
N.AstrupA.DeaconC
GLP1 Wegovy (semaglutide) and GIP Mounjaro (tirzepatide) injections are not currently licensed as smoking-cessation treatments
00748-8/asset/30c158de-333f-4fe9-aa2d-c5fee985f3f0/main.assets/gr2b_lrg.jpg)
Interestingly, in rat ileum preparations, administration of atropine was not able to block GIP-induced GLP-1 secretion [335]
Each 1 percentage point weight gain after GLP-1 discontinuation was tied with a 2.3% higher likelihood for therapy reinitiation among adults with type 2 diabetes and 2.8% higher odds for restarting a GLP-1 for those without type 2 diabetes
